Loading...

PODCAST

Pharmaceutical Executive

Pharmaceutical Executive Podcast

The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and PharmExec.com to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry.

science life sciences

All Episodes

2:00

Pharmaceutical Executive Daily: Cognito Therapeutics...

Pharmaceutical Executive ·

2026/03/05

In today’s Pharmaceutical Executive Daily, Cognito Therapeutics and Nexcure secure new financing rounds to advance their pipelines, artificial intelligence and large language models reshape pharmacovigilance and drug safety monitoring, and Eli Lilly launches a new Employer Connect platform to expand obesity treatment coverage options.

en-us

1:57

Pharmaceutical Executive Daily: Pharma Industry's AI...

Pharmaceutical Executive ·

2026/03/04

In today’s Pharmaceutical Executive Daily, Antengene and UCB enter a billion-dollar global licensing agreement for a bispecific T-cell engager, Teva signs a $400 million strategic growth capital agreement with Blackstone Life Sciences, and industry leaders explore the technological renaissance driven by AI integration.

en-us

16:53

The Ongoing Impact of MFN Pricing

Pharmaceutical Executive ·

2026/03/04

Alice Valdur Curan discusses how the industry continues to strategize around this complicated order.

en-us

1:50

Pharmaceutical Executive Daily: Novo Nordisk Commits...

Pharmaceutical Executive ·

2026/03/03

In today’s Pharmaceutical Executive Daily, industry leaders examine how to measure AI’s return on investment across the life sciences value chain, Novo Nordisk commits $506 million to expand its Ireland manufacturing facility, and Bavarian Nordic CEO Paul Chaplin announces plans to step down.

en-us

1:51

Pharmaceutical Executive Daily: FDA Approves Palynziq...

Pharmaceutical Executive ·

2026/03/02

In today’s Pharmaceutical Executive Daily, the FDA approves an expanded indication for Palynziq in patients aged 12 and older, Sogroya becomes the first and only weekly long-acting growth hormone approved for pediatric use, and experts examine how real-world data strengthens natural history disease research.

en-us

1:43

Pharmaceutical Executive Daily: FDA Approves Hernexeos

Pharmaceutical Executive ·

2026/02/27

In today’s Pharmaceutical Executive Daily, the FDA approves Hernexeos under a national priority voucher program, industry leaders explore the expansion of direct-to-consumer HIV prevention strategies, and Dupixent gains FDA approval for allergic fungal rhinosinusitis.

en-us

1:41

Pharmaceutical Executive Daily: Alkermes' CEO...

Pharmaceutical Executive ·

2026/02/26

In today’s Pharmaceutical Executive Daily, Alkermes outlines its CEO succession plan following Richard Pops’ retirement announcement, leadership changes continue at Sarepta Therapeutics and Rivus Pharmaceuticals, and Boehringer Ingelheim secures an exclusive license for a preclinical small-molecule program.

en-us

10:01

The Ron Lanton Report: Is Healthcare Consolidation...

Pharmaceutical Executive ·

2026/02/26

The episode will explore structural implications for supply chains, distribution models, and international strategy, not a political discussion, but a forward-looking planning lens.

en-us

1:59

Pharmaceutical Executive Daily: FDA Approves Braftovi

Pharmaceutical Executive ·

2026/02/25

In today’s Pharmaceutical Executive Daily, the FDA approves Braftovi for mutant metastatic colorectal cancer, Novo Nordisk and GSK announce major deal activity in a mergers and acquisitions roundup, and UK regulators confiscate thousands of doses of illegal weight-loss medicines.

en-us

2:22

Pharmaceutical Executive Daily: Novo Nordisk...

Pharmaceutical Executive ·

2026/02/24

In today’s Pharmaceutical Executive Daily, AbbVie invests $380 million to expand API manufacturing capacity while Bora Pharmaceuticals and GSK enter a five-year manufacturing agreement, Novo Nordisk announces significant price reductions for its leading GLP-1 therapies, and Astellas enters a billion-dollar global collaboration with Vir Biotechnology to advance PSMA-targeting cancer treatments.

en-us

2:03

Pharmaceutical Executive Daily: BioNTech Files Patent...

Pharmaceutical Executive ·

2026/02/20

In today’s Pharmaceutical Executive Daily, BioNTech files a patent infringement lawsuit against Moderna, the Supreme Court rules against a large number of Trump-era tariffs, and the FDA approves a Calquence–venetoclax combination for certain blood cancers.

en-us

1:59

Pharmaceutical Executive Daily: FDA Plans to Remove...

Pharmaceutical Executive ·

2026/02/19

In today’s Pharmaceutical Executive Daily, the FDA reportedly removes its two-study requirement for new drug approvals, Hims & Hers enters a $1 billion agreement to acquire Eucalyptus, and experts examine how FDA can help ease early-stage clinical trial bottlenecks.

en-us

1:55

Pharmaceutical Executive Daily: FDA Initiates Review...

Pharmaceutical Executive ·

2026/02/18

In today’s Pharmaceutical Executive Daily, the FDA begins reviewing Moderna’s seasonal flu vaccine under a revised regulatory approach, Eli Lilly signs a $100 million licensing agreement with CSL for an anti- IL-6 monoclonal antibody., and Southern Florida emerges as a growing biotech hub.

en-us

1:49

Pharmaceutical Executive Daily: FDA Approves New...

Pharmaceutical Executive ·

2026/02/17

In today’s Pharmaceutical Executive Daily, the FDA approves a monthly dosing schedule for Rybrevant Faspro, HHS Secretary Robert F. Kennedy Jr. revises the agency’s leadership team, and industry expert Sandy Tammisetty discusses what it takes to deliver actual value in today’s pharmaceutical landscape.

en-us

1:41

Pharmaceutical Executive Daily: Disc Medicine...

Pharmaceutical Executive ·

2026/02/16

In today’s Pharmaceutical Executive Daily, the FDA issues a Complete Response Letter for Disc Medicine’s bitopertin in EPP, Edwards Lifesciences lifts its anti-copycat policy, and industry leaders examine how to scale global medical digital transformation while ensuring local fit.

en-us

1:26

Pharmaceutical Executive Daily: Eli Lilly's $1.5...

Pharmaceutical Executive ·

2026/02/13

In today’s Pharmaceutical Executive Daily, Eli Lilly builds a $1.5 billion stockpile of Orforglipron ahead of an FDA decision, PTC Therapeutics withdraws and plans to resubmit its Translarna NDA, and a former AstraZeneca executive is charged with multiple offenses in China.

en-us

1:44

Pharmaceutical Executive Daily: FDA Issues...

Pharmaceutical Executive ·

2026/02/11

In today’s Pharmaceutical Executive Daily, the FDA issues a refusal-to-file letter to Moderna for its seasonal influenza vaccine as the company secures a long-term agreement in Mexico, industry leaders assess China’s evolving role in global pharma strategy, and the FDA makes a decision on Keytruda in platinum-resistant ovarian cancer.

en-us

1:52

Pharmaceutical Executive Daily: Specialized Wealth...

Pharmaceutical Executive ·

2026/02/10

In today’s Pharmaceutical Executive Daily, frontline biopharma sales professionals are increasingly turning to specialized wealth management advisory services, QuantX Biosciences and Pandorum Technologies close Series B financing rounds, and Iambi enters a $1 billion collaboration with Takeda to advance small-molecule programs.

en-us

17:43

Bets and Balances: Riding the Risk-and-Innovation...

Pharmaceutical Executive ·

2026/02/10

In a podcast conversation with Pharm Exec, Ken Banta, founder and CEO of The Vanguard Network, and Andrew Hall, CEO of Consano Bio, discuss what effective leadership looks like in today’s volatile capital and regulatory climates for emerging biotechs. Part 1 of the conversation explores why Banta and Hall believe CEOs of these companies must act as stabilizers and translators—balancing risk with opportunity and turning complex scientific innovation into clear strategy for investors, regulators, and

en-us

1:53

Pharmaceutical Executive Daily: Hims & Hers Removes...

Pharmaceutical Executive ·

2026/02/09

In today’s Pharmaceutical Executive Daily, Hims & Hers withdraws access to its compounded semaglutide pill following a controversy filled launch, next-generation trial designs increasingly integrate real-world data, and Eli Lilly enters an $8 billion strategic collaboration involving Innovent and Orna Therapeutics.

en-us

463 results

Similar Podcasts

Rabbit Hole of Research

Jotham Austin, II PhD, Nick Elizalde,...

La Science CQFD

France Culture

A Moment of Science

Indiana Public Media

Physics World Weekly Podcast

Physics World

La Science, CQFD

France Culture